Colorectal cancer (CRC), the third and fourth most common cancer in women and men, respectively, causes 610 000 deaths per year worldwide ([@bib11]). Nearly 50% of patients with CRC develop tumour recurrence ([@bib41]; [@bib44]; [@bib23]), and the primary cause of death is liver metastasis ([@bib12]). Genetic testing for *KRAS* somatic mutations in patients with advanced CRC has become a routine clinical practice ([@bib5]; [@bib3]; [@bib13]; [@bib21]; [@bib24]), and epidermal growth factor receptor (EGFR) inhibitors are now recommended only for use in patients with *KRAS* wild-type CRC tumours ([@bib2]). However, even among patients with *KRAS* wild-type tumours, some patients do not respond to EGFR inhibitors. One reason for this may be discordance of the *KRAS* mutation status between primary tumours and corresponding metastases ([@bib1]; [@bib30]; [@bib31]). In addition, there is emerging evidence that mutations in *BRAF* and *PIK3CA* are associated with resistance to EGFR-targeted agents ([@bib9]; [@bib33]; [@bib8]; [@bib27]). Thus, a thorough understanding of molecular alterations in primary tumours and corresponding metastases of CRCs may have considerable clinical implications.

The development of CRC is a multistep process arising from the accumulation of genetic and epigenetic alterations ([@bib42]). The chromosomal instability pathway and microsatellite instability (MSI) pathway are the two recognised pathways of CRC carcinogenesis ([@bib25]). Along with genetic mutations, epigenetic changes such as DNA methylation and histone modification are important for carcinogenesis and tumour development ([@bib18]; [@bib39]; [@bib10]). Cancer cells exhibit two types of DNA methylation alterations: global DNA hypomethylation and site-specific CpG island promoter hypermethylation ([@bib20]; [@bib38]; [@bib32]). Global DNA hypomethylation appears to have a crucial role in genomic instability ([@bib6]), leading to cancer development and progression ([@bib14]; [@bib16]; [@bib37]). Because the LINE-1 retrotransposon constitutes a substantial portion (approximately 17%) of the human genome, the methylation status of LINE-1 reflects the global DNA methylation level ([@bib7]).

The tumour LINE-1 methylation level is attracting interest as a useful marker for predicting CRC prognosis. [@bib29] previously found that the degree of LINE-1 hypomethylation is linearly associated with aggressive tumour behaviour and observed an approximately 5-fold increase in cancer-specific mortality associated with tumours at the low end of the methylation spectrum compared with those at the high end. In addition, LINE-1 hypomethylated CRC has been associated with young age at onset ([@bib4]) and CRC familial clustering ([@bib15]). However, no study has yet examined the LINE-1 methylation status in metastatic tumours, including both metachronous tumours and synchronous tumours, or assessed the heterogeneity of the LINE-1 methylation level within a CRC tumour.

The aims of this study were to: (1) evaluate the LINE-1 methylation status in metastatic lesions from CRCs; the mutational status of the *KRAS*, *BRAF*, and *PIK3CA* genes; and the MSI status; (2) compare the LINE-1 methylation level of the superficial area with that of the invasive front area within the primary tumour; and (3) examine the prognostic impact of LINE-1 methylation levels in metastatic liver tumours.

Materials and methods
=====================

Study subjects
--------------

A total of 134 consecutive patients with liver metastases from CRC who underwent hepatic resection at Kumamoto University Hospital between 2000 and 2012 were initially enrolled in this study. Four patients were excluded owing to the unavailability of adequate tissue specimens. Eighty-eight patients were excluded because they had undergone preoperative chemotherapy ([Figure 1A](#fig1){ref-type="fig"}). We analysed 42 liver metastases from patients who had not undergone preoperative chemotherapy, 26 matched primary tumours, and 6 matched lymph node (LN) metastases ([Figure 1B](#fig1){ref-type="fig"}). Patients were observed at 1--6-month intervals until death or 31 December 2012, whichever came first. Tumour staging was performed according to the International Union Against Cancer TNM system. Written informed consent was obtained from each subject, and the study procedures were approved by the institutional review board.

DNA extraction and sodium bisulfite treatment
---------------------------------------------

Hematoxylin- and eosin-stained slides of the tumours were reviewed by one pathologist, who marked the areas of the tumour and normal tissue. In addition, superficial areas and invasive front areas were marked separately in six cases ([Figure 1C](#fig1){ref-type="fig"}). Genomic DNA was extracted from tumour lesions enriched with neoplastic cells without adjacent normal tissue using a formalin-fixed, paraffin-embedded tissue kit (Qiagen, Valencia, CA, USA). Genomic DNA was extracted from the tumour and modified with sodium bisulfite using an EpiTect Bisulfite Kit (Qiagen).

Whole-genome amplification
--------------------------

Whole-genome amplification is a useful technique for preserving original study material for many different assays and future studies. In whole-genome amplification, genomic DNA is amplified by PCR using primers with a random sequence of 15 nucleotides. Each PCR mix contained 40 pmol of the random primers, 1.0 nmol of each dNTP, 2.0 mmol l^−1^ of MgCl~2~, 1 × PCR buffer (Applied Biosystems, Foster City, CA, USA), 0.25 U of AmpliTaq Gold 360 (Applied Biosystems), and 5 *μ*l of template DNA solution in a total volume of 50 *μ*l. PCR conditions were as follows: initial denaturation at 95 °C for 10 min; 50 cycles of 95 °C for 60 s, annealing (37 °C for 2 min), ramping from 37--55 °C (0.1 °C s^−1^), 55 °C for 2 min, and 68 °C for 30 s; and a final extension at 72 °C for 7 min.

Pyrosequencing to measure LINE-1 methylation
--------------------------------------------

PCR and subsequent pyrosequencing for LINE-1 were performed as previously described by [@bib28], [@bib29]) using the PyroMark Kit (Qiagen) ([@bib4]; [@bib17]). This assay amplifies a region of the LINE-1 element (position 305--331 in accession no. X58075), which includes four CpG sites. The PCR conditions were 45 cycles of 95 °C for 20 s, 50 °C for 20 s, and 72 °C for 20 s, followed by 72 °C for 5 min. The biotinylated PCR product was purified and made single stranded to act as a template in a pyrosequencing reaction using the Pyrosequencing Vacuum Prep Tool (Qiagen). Pyrosequencing reactions were performed in the PyroMark Q24 System (Qiagen). The nucleotide dispensation order was 5′-ACTCAGTGTGTCAGTCAGTTAGTCTG-3′. The non-CpG cytosine in LINE-1 repetitive sequences has been documented to be rarely methylated. Thus, complete conversion of cytosine at a non-CpG site ensured successful bisulfite conversion. The amount of C relative to the sum of the amounts of C and T at each CpG site was calculated as a percentage (i.e., 0--100%). The average of the relative amounts of C in the four CpG sites was used as the overall LINE-1 methylation level in a given tumour. We have validated our LINE-1 methylation pyrosequencing assay in the published literature ([@bib19]).

Pyrosequencing for *KRAS*, *BRAF*, and *PIK3CA* mutations
---------------------------------------------------------

Pyrosequencing for *KRAS*, *BRAF*, and *PIK3CA* mutations was performed as previously described using the PyroMark kit (Qiagen) ([@bib34], [@bib35]). We used PCR amplification and the pyrosequencing primers shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Microsatellite instability analysis
-----------------------------------

Microsatellite instability analysis was performed using the BAT25 primer set (sense, 5′-TCGCCTCCAAGAATGTAAGT-3′ and antisense, 5′-TCTGCATTTTAACTATGGCTC-3′) and the BAT26 primer set (sense, 5′-TGACTACTTTTGACTTCAGCC-3′ and antisense, 5′-AACCATTCAACATTTTTAACCC-3′). The sense primer was labelled with FAM. PCR was performed in a final volume of 25 *μ*l containing 1 × PCR buffer, 2.0 mmol l^−1^ of MgCl~2~, 0.2 *μ*mol l^−1^ of dNTPs, 0.2 *μ*mol l^−1^ of each primer, 1.25 U of AmpliTaq Gold 360, and 1 *μ*l of DNA. The thermal conditions were 95 °C/15 min followed by 45 cycles (95 °C/30 s, 60 °C/30 s, and 72 °C/30 s) and a final extension at 72 °C/7 min. The dye-labelled PCR products were analysed with an ABI PRISM 3100 Genetic Analyzer using Genescan 3·7 software (Applied Biosystems). A total of 0.5 *μ*l of the PCR product was mixed with 9.25 *μ*l of highly deionized formamide and 0.25 *μ*l of DNA Size Standard LIZ 500/(−250) (both obtained from Applied Biosystems, Darmstadt, Germany). This mixture was denatured for 3 min at 95 °C, immediately put on ice, and separated using an ABI 3130 Genetic Analyzer. Results were analysed using GeneMapper software (Applied Biosystems).

Both tumoural and normal samples were analysed. Negative (HT29 cells) and positive (HCT116 and HCT15 cells) controls for MSI were included in all analyses. Samples were divided into two groups: those with one or more of the two markers displaying MSI and those with no instability (microsatellite-stable).

Statistical methods
-------------------

For the statistical analyses, we used JMP software (version 9; SAS Institute, Cary, NC, USA). All *P*-values were two-sided. To compare the means, we performed the *t*-test assuming unequal variances. For the survival analysis, the Kaplan--Meier method was used to assess the survival time distribution, and the log-rank test was used.

Results
=======

Pyrosequencing assay for LINE-1 methylation status in liver metastases
----------------------------------------------------------------------

We first quantified the LINE-1 methylation level in 42 liver metastases and obtained valid results in all cases. Representative pyrograms for LINE-1 are shown in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}. The distribution of the LINE-1 methylation level in the 42 liver metastases on a 0--100 scale was as follows: mean, 67.3; median, 68.5; s.d., 10.9; range, 37.1--90.1; and interquartile range, 59.5--74.3. The LINE-1 methylation level was not associated with any clinical, epidemiological, or pathological characteristics including sex, age, year of operation, tumour size, detection of metastases, postoperative chemotherapy, and stage (all *P*\>0.079) ([Table 1](#tbl1){ref-type="table"}). Importantly, the LINE-1 methylation level did not differ between synchronous tumours and metachronous tumours (*P*=0.217).

LINE-1 methylation level between primary and metastatic lesions of CRCs
-----------------------------------------------------------------------

Next, we examined the LINE-1 methylation level in 26 matched primary tumours. The distribution of the LINE-1 methylation level in the 26 matched primary tumours was as follows: mean, 69.0; median, 70.5; s.d., 11.3; and range, 40.4--82.2. The LINE-1 methylation level of liver metastases was significantly associated with that of matched primary tumours (*n*=26; Pearson\'s correlation coefficient *r*=0.70; *P*=0.0006) ([Figure 2](#fig2){ref-type="fig"}). The distribution of the LINE-1 methylation level in the six matched LN metastases was as follows: mean, 71.0; median, 71.9; s.d., 9.37; and range, 56.3--81.9. In six cases, the difference in the LINE-1 methylation level between primary tumours and LN metastases ranged from 0.3 to 12.8 ([Figure 3A](#fig3){ref-type="fig"}). Given that the LINE-1 methylation level in CRC primary tumours was highly variable (23.1--90.3 in 869 tumours) ([@bib28]), this difference may be so small as to be insignificant.

Heterogeneity of LINE-1 methylation level
-----------------------------------------

To evaluate the heterogeneity of the LINE-1 methylation level within primary tumours, we investigated the LINE-1 methylation levels in both superficial areas and invasive front areas ([Figure 1C](#fig1){ref-type="fig"}). We found that the LINE-1 methylation level in superficial areas was significantly associated with that in invasive front areas (*n*=6; *P*=0.0048) ([Figure 3B](#fig3){ref-type="fig"}). The difference between the methylation level in the superficial area and that in the invasive front area was within 7.0 in all six cases, suggesting the absence of heterogeneity of the LINE-1 methylation level within a given primary tumour.

*KRAS*, *BRAF*, and *PIK3CA* mutations and MSI status in primary and metastatic lesions of CRCs
-----------------------------------------------------------------------------------------------

For a better understanding of the differences in molecular alterations between primary and metastatic tumours, we examined the *KRAS*, *BRAF*, and *PIK3CA* mutational status and the MSI status in 26 primary tumours, 26 matched liver metastases, and 6 LN metastases. *KRAS* mutation was detected in 6 out of 26 primary lesions: 5 in c.35G\>A (codon 12 GAT) and 1 in c.35G\>T (codon 12 GTT). In 6 out of 26 cases, the *KRAS* mutational status in primary tumours was confirmed by using a TheraScreen K-RAS Mutation Kit (Qiagen), the Scorpion Amplified Refractory Mutation System technology, which incorporates a unique bifunctional fluorescent primer/probe molecule (Scorpion probe). The results supported the reliability of our pyrosequencing assay for *KRAS*-mutation detection ([Figure 4A](#fig4){ref-type="fig"}). *KRAS* mutation was detected in 8 out of 32 metastatic lesions: 7 in c.35G\>A (codon 12 GAT) and 1 in c.35G\>T (codon 12 GTT). Twenty-four cases showed a concordant *KRAS* mutation status in the primary tumour and metastatic tumour, whereas two cases (6%) showed a discordant mutation status. In addition, we evaluated the *KRAS* mutation status in superficial areas and invasive front areas within six primary tumours, and found that all six cases showed a concordant mutation status between the two lesions.

The mutational status in *BRAF* exon 15 (V600E) was examined in 58 tumour lesions (26 primary tumours, 26 liver metastases, and 6 LN metastases) of CRC by pyrosequencing technology. Valid results were obtained in all 58 tissues. All 58 lesions harboured the wild type at codon 600 in *BRAF* exon 15.

*PIK3CA* mutation was detected in 14 out of 26 primary lesions and 13 out of 32 metastatic lesions ([Figure 4B](#fig4){ref-type="fig"}). Twenty-eight liver and LN metastases showed a *PIK3CA* mutational status identical to that of the matched primary tumours. A discordant status of *PIK3CA* mutation between the superficial area and invasive front area was observed in only one case.

The MSI pathway is a recognised pathway of CRC development. Thus, we examined the MSI status in 26 primary tumours and 32 metastatic tumours. Microsatellite instability was detected in 3 out of 26 primary tumours and 4 out of 32 metastatic tumours ([Figure 4C](#fig4){ref-type="fig"}). Thirty-one liver and LN metastases showed an MSI status identical to that of the matched primary tumours. In addition, heterogeneity of the MSI status was not observed between superficial areas and invasive front areas within six primary tumours.

LINE-1 methylation level was not associated with *KRAS*, *PIK3CA*, and MSI status in metastatic tumours (*P*=0.068 for *KRAS*, *P*=0.54 for *PIK3CA*, and *P*=0.57 for MSI; [Table 2](#tbl2){ref-type="table"}).

LINE-1 methylation level in liver metastases and patient survival
-----------------------------------------------------------------

Overall survival was defined as the time between the date of the hepatic resection and the date of death. During an adequate follow-up period among the 42 patients, there were 12 deaths, including 10 deaths that were confirmed to be attributable to CRC. The median follow-up time for censored patients was 3·9 years. The LINE-1 methylation level in liver metastases was divided into two groups: the hypermethylation group (⩾69.0, *n*=21) and the hypomethylation group (37.1--68.5, *n*=21). Kaplan--Meier analysis showed a similar overall mortality rate between the two groups (*P*=0.432) ([Figure 5](#fig5){ref-type="fig"}).

Discussion
==========

This is the first study to compare LINE-1 methylation levels (i.e., global DNA methylation levels) in primary CRC tumours with those in liver metastases including both metachronous tumours and synchronous tumours. Liver metastases showed LINE-1 methylation levels similar to those of primary tumours. In addition, we compared the LINE-1 methylation level of superficial areas with that of invasive front areas within primary tumours and found the absence of heterogeneity of the LINE-1 methylation level. These results may suggest that CRC cells acquire the tumoural characteristic of global DNA hypomethylation during the early stage of tumour development and that this characteristic is preserved throughout the process of cancer invasion and metastasis.

The tumour LINE-1 methylation level is attracting interest as a useful marker for predicting CRC prognosis ([@bib29]). In addition, the LINE-1 methylation status may be a predictive marker for the response to fluoropyrimidines in a certain subgroup of CRC ([@bib22]). In clinical practice, molecular analyses of tumour samples are generally performed using either biopsy specimens obtained before surgery or surgically resected tissue. Because tissue from metastatic and/or recurrent tumours is not easily accessible, results obtained from analysis of the primary tumour are always used in clinical decision-making regarding treatment of metastatic/recurrent CRCs. In this study, we have shown that LINE-1 methylation levels in metastatic liver tumours are similar to those in primary tumours, allowing for the potential clinical application of the LINE-1 methylation level in CRCs. Further studies are required to establish whether LINE-1 methylation can be used in personalised medicine for CRC.

Whether the LINE-1 methylation level is associated with the CRC tumour stage remains controversial. [@bib36] showed a linear correlation between LINE-1 demethylation progression and TNM stage progression, thus suggesting that the genomic methylation level continuously decreases during CRC development and progression. In contrast, [@bib28] demonstrated that LINE-1 methylation levels were not associated with tumour stage (stage I--IV) in 869 population-based CRC tumours. In the current study, we found identical LINE-1 methylation levels between primary tumours and liver/LN metastases, as well as the absence of heterogeneity of the LINE-1 methylation level within primary tumours; these results are in agreement with those of the previous study by [@bib26]. Interestingly, we also found that LINE-1 methylation levels did not differ between synchronous tumours and metachronous tumours, supporting the view that the LINE-1 methylation level is continuously preserved even during the long-term natural history of CRC development. These findings by [@bib28], [@bib26], and us may suggest that the onset of LINE-1 demethylation occurs at an early stage of CRC development and that the LINE-1 methylation level is relatively stable during CRC progression.

To the best of our knowledge, this is the first study to examine the prognostic significance of the LINE-1 methylation level in metastatic tumours. Given the strong relationship between LINE-1 hypomethylation in primary CRC tumours and a poor prognosis ([@bib29]), we first speculated that LINE-1 hypomethylation in metastatic CRC tumours might be associated with a shorter overall survival. However, we found no association between the LINE-1 methylation level and clinical outcome. One possible reason for this result may be the effect of postoperative chemotherapy. In this study, 30 patients received various types of postoperative chemotherapy, whereas 12 patients received no postoperative chemotherapy. [@bib22] showed that patients with low LINE-1 methylation levels who were treated with adjuvant chemotherapy survived for a longer period of time than did patients treated by surgery alone, whereas a survival benefit from chemotherapy was not observed for patients with high LINE-1 methylation levels. Thus, the prognostic impact of the LINE-1 methylation level in metastatic tumours on clinical outcome may be influenced by the presence or absence of postoperative chemotherapy or the type of chemotherapy. In addition, we acknowledge that this study is limited by its small sample size. We are currently planning a further large-scale study on LINE-1 methylation levels, chemotherapeutic effects, and patient survival in CRC.

With the development of cancer therapies that specifically target molecular alterations that mediate cancer progression, genotyping of patients with advanced CRC has become a component of routine clinical practice. Specifically, *KRAS* mutational testing has been incorporated into several clinical practice guidelines for the treatment of patients with metastatic CRC. The National Comprehensive Cancer Network recommends testing either the primary tumour or a site of metastasis. This recommendation is based on several studies that found a high *KRAS* mutational concordance (\>95%) between primary CRCs and metastases. [@bib40] reported that primary tumours and matched metastases showed a high concordance rate (\>90%) for five genes, including the *KRAS*, *BRAF*, and *PIK3CA* genes. [@bib43] reported that primary tumours and matched metastases showed a high concordance rate (86%) for MSI. In the current study, the concordance rates of the *KRAS*, *BRAF*, and *PIK3CA* mutations and the MSI status were almost identical to those of previous reports. We also examined the heterogeneity within primary tumours and found that the *KRAS* and *BRAF* status and the MSI status were concordant within the primary tumour in all cases. Interestingly, the *PIK3CA* mutation status in primary tumours showed discordance between the superficial area and invasive front area in only one case. A model in which alterations in *KRAS* and *BRAF* occur early in CRC pathogenesis is proposed. Considering that the time at which *PIK3CA* mutation occurs is unknown, our finding on the discordance of the *PIK3CA* mutation should be confirmed by independent cohorts with larger sample sizes.

The relationship between LINE-1 methylation level and molecular alterations in CRCs is important. [@bib28] have shown that LINE-1 methylation level is higher in MSI-positive tumours than in MSI-negative tumours, and higher in *BRAF* mutation tumours than in *BRAF* wild-type tumours in primary CRCs. [@bib4] have demonstrated no significant relationship between *KRAS* and *PIK3CA* mutations and LINE-1 methylation level in primary CRCs. In this study of metastatic CRC tumours, LINE-1 methylation level was not associated with MSI status and *KRAS* and *PIK3CA* mutations. However, this study was limited by small sample size. In addition, *BRAF* mutation was not detected in 26 metastatic CRC tumours. Our findings need to be confirmed by independent studies in the future.

In summary, we found that liver and LN metastases showed LINE-1 methylation levels similar to those of the primary tumours. In addition, heterogeneity of the LINE-1 methylation level within primary tumours was not observed. Taken together, these results show that the onset of LINE-1 demethylation occurs at an early stage of CRC development and that the LINE-1 methylation level is relatively stable during CRC progression.
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![(**A**) Flow chart of the study population. (**B**) In this study, we examined the LINE-1 methylation level in 26 primary tumours, 26 matched liver metastases, and 6 matched LN metastases. (**C**) Macrodissection to separate the superficial area from the invasive front area.](bjc2013289f1){#fig1}

![Correlation between the LINE-1 methylation level in primary tumours and that in liver metastases. The LINE-1 methylation level in liver metastases was significantly associated with that in matched primary tumours (*n*=26; Pearson\'s correlation coefficient *r*=0.70; *P*=0.0006).](bjc2013289f2){#fig2}

![LINE-1 methylation level in superficial and invasive areas of primary tumours, matched LN metastases, and matched liver metastases (*n*=6). (**A**) In each case, the LINE-1 methylation level of the LN and liver metastases was similar to that in the matched primary tumours. (**B**)The LINE-1 methylation level in superficial areas was significantly associated with that in the matched invasive areas within primary tumours (*n*=6; Pearson\'s correlation coefficient, *r*=0.95; *P*=0.0048).](bjc2013289f3){#fig3}

![Gene mutation analysis in 26 paired primary CRCs and liver metastases and 6 matched LN metastases. The wild type is shown in blue, and the mutational type is shown in red. The white square denotes the lack of a specimen. (**A**) *KRAS* mutation status. Six primary tumours showed the *KRAS* mutation type. Thirty liver and LN metastases showed a *KRAS* status identical to that of the matched primary tumours. The *KRAS* status was confirmed by Scorpion Amplified Refractory Mutation System (ARMS) technology and supported the reliability of the pyrosequencing assay for *KRAS* mutation detection in six cases. (**B**) *PIK3CA* mutation status. Seven primary tumours showed the *PIK3CA* mutation type. Twenty-eight liver and LN metastases showed a *PIK3CA* status identical to that of the matched primary tumours. (**C**) Microsatellite instability status. Three primary tumours showed MSI. Thirty-one liver and LN metastases showed an MSI status identical to that of the matched primary tumours.](bjc2013289f4){#fig4}

![Kaplan--Meier curves for overall survival in the two groups of LINE-1 methylation in metastatic CRC tumours. The hypomethylation (37.1--68.5%, *n*=21) group experienced an overall mortality similar to that of the hypermethylation group (⩾69.0%, *n*=21).](bjc2013289f5){#fig5}

###### LINE-1 methylation level and clinical or epidemiological features of liver metastases from colorectal cancer

  **Clinical or epidemiological features**    ***N*** **(%)**[a](#t1-fn2){ref-type="fn"}  **LINE-1 methylation levelmean (%)**    ***P*****-value**
  ------------------------------------------ -------------------------------------------- -------------------------------------- -------------------
  All cases                                                       42                      67.3                                             
  **Age**                                                                                                                        
  \<65                                                        25 (60.0%)                  67.2                                          0.798
  ⩽65                                                         17(40.0%)                   67.5                                             
  **Sex**                                                                                                                        
  Male                                                        26 (61.9%)                  67.7                                          0.786
  Female                                                      16 (38.1%)                  66.6                                             
  **Year of operation**                                                                                                          
  2001--2006                                                  24 (57.1%)                  67.8                                          0.657
  2007--2012                                                  18 (42.9%)                  66.6                                             
  **Tumour size (mm)**                                                                                                           
  35\<                                                        21 (50.0%)                  67.0                                          0.841
  ⩾35                                                         21 (50.0%)                  67.6                                             
  **Detection of metastases**                                                                                                    
  Synchronous                                                 15 (35.7%)                  64.7                                          0.217
  Metachronous                                                27 (64.3%)                  68.8                                             
  **Postoperative chemotherapy**                                                                                                 
  Yes                                                         32 (76.2%)                  68.9                                          0.079
  No                                                          10 (23.8%)                  62.4                                             
  **Stage**                                                                                                                      
  I                                                            4 (9.5%)                   70.7                                          0.161
  II                                                          11 (26.2%)                  72.7                                             
  III                                                         11 (26.2%)                  65.0                                             
  IV                                                          16 (38.1%)                  64.4                                             

There is no significant relation between LINE-1 and any of the clinical or epidemiological features examined.

\% indicates the proportion of cases with a specific clinical or epidemiological feature.

###### LINE-1 methylation level and molecular features of liver metastases from colorectal cancer

  **Molecular features**    ***N***  **LINE-1 methylation level mean (%)**    ***P*****-value**
  ------------------------ --------- --------------------------------------- -------------------
  All cases                   26     67.8                                              
  ***KRAS* mutation**                                                        
  Negative                    20     65.7                                           0.068
  Positive                     6     75.1                                              
  ***PIK3CA* mutation**                                                      
  Negative                    19     66.5                                           0.544
  Positive                     7     71.4                                              
  **MSI status**                                                             
  Negative                    22     67.1                                           0.570
  Positive                     4     71.9                                              

Abbreviation: MSI=microsatellite instability.
